Personalized nutrition therapy using continuous glucose monitoring for type 2 diabetes
Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus
This study is testing if using continuous glucose monitoring along with personalized nutrition therapy can help people with type 2 diabetes better control their blood sugar compared to just nutrition therapy alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT06465693 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of personalized nutrition therapy guided by continuous glucose monitoring (CGM) in improving glycemic control for individuals with type 2 diabetes. Participants will be divided into two groups: one receiving CGM alongside nutrition therapy and the other receiving nutrition therapy alone. The goal is to assess whether CGM can enhance dietary interventions by tailoring them to individual blood glucose responses, thereby improving patient outcomes and satisfaction. The study addresses the variability in blood glucose responses to meals, which is often overlooked in standard nutrition plans.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of type 2 diabetes and an HbA1c level between 7.0% and 9.5%.
Not a fit: Patients with type 1 diabetes, those on certain diabetes medications, or individuals with significant health issues affecting adherence may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better glycemic control and improved quality of life for patients with type 2 diabetes.
How similar studies have performed: Previous studies have shown promising results using continuous glucose monitoring in dietary interventions for diabetes, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age * Have a previous diagnosis of type 2 diabetes * HbA1c of 7.0 - 9.5% * Stable medications for diabetes for at least 3 months prior to enrollment, with no plans to change medications or doses during the intervention period. Exclusion Criteria: * Type 1 diabetes * Treatment with insulin, sulfonylurea, or meglitinide * Use of a nondiabetic medication affecting blood glucose (e.g. corticosteroid) * BMI \<25 kg/m2 * Weight change \>5 pounds in the 3 months prior to enrollment * Estimated glomerular filtration rate \<60 ml/minute/1.73 m2 * Pregnant or breastfeeding * Anemia (which affects HbA1c) * Presence of any disease that would make adherence to the protocol difficult
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Anne Bantle, MD,MS — University of Minnesota
- Study coordinator: Anne Bantle, MD, MS
- Email: bant0015@umn.edu
- Phone: 612-625-8673
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.